VANTAGE014_4: VANTAGE014, figure 4

VANTAGE014_4R Documentation

VANTAGE014, figure 4

Description

Kaplan-Meier digitized data from VANTAGE014, figure 4 (PMID 25800891). A reported sample size of 661 for a primary endpoint of OS/safety in lung cancer.

Usage

VANTAGE014_4

Format

A data frame of 661 observations and 3 variables:

time event time (in weeks)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (placebo, vorinostat)

Source

Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 2015; 16: 447–56.

Examples

summary(VANTAGE014_4)

kmplot(VANTAGE014_4)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.